{"id":"ta-650","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL3697320","moleculeType":"Small molecule","molecularWeight":"326.33"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TA-650 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"TA-650 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:11.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01680159","phase":"PHASE3","title":"A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-07","conditions":"Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized)","enrollment":51},{"nctId":"NCT00691028","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":327},{"nctId":"NCT01585155","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-02","conditions":"Pediatric Ulcerative Colitis","enrollment":21},{"nctId":"NCT01580670","phase":"PHASE3","title":"Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-03","conditions":"Pediatric Crohn's Disease","enrollment":14},{"nctId":"NCT00805766","phase":"PHASE3","title":"Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":39},{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT01532570","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-01","conditions":"Behcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease","enrollment":18},{"nctId":"NCT02606045","phase":"PHASE3","title":"Minimize Menorrhagia in Women With Von Willebrand Disease","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2019-02-07","conditions":"Von Willebrand Diseases","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Infliximab"],"phase":"phase_3","status":"active","brandName":"TA-650","genericName":"TA-650","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TA-650 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}